Erzurum

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Gastric and oesophageal cancer4 trials
• Liver and biliary tract cancer4 trials
• Childhood cancers1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Active, not recruiting3 trials
• Recruiting3 trials
• Not yet recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• AstraZeneca8 trials

Running trials

• Recruiting

  CHARM Hepatocellular Carcinoma MEA Study

  NCT07650773· AstraZeneca· Source

• Recruiting

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· Phase 3· AstraZeneca· Source

• Recruiting

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  NCT06764875· Phase 3· AstraZeneca· Source

• Active, not recruiting

  AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

  NCT06346392· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

  NCT06109779· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

  NCT04550260· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer3 recruiting
• Childhood cancers1 recruiting
• Gastric and oesophageal cancer1 recruiting

Closed trials

• Recruiting

  A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

  NCT07069712· Phase 2· AstraZeneca· Source